Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Breast Neoplasms 2 Triple Negative Breast Neoplasms 1 Rectal Neoplasms 1 Pathologic Complete Response 1 Neuroendocrine Tumors 1 Nasopharyngeal Carcinoma 1 Lymphoma, Large B-Cell, Diffuse 1 Lung Neoplasms 1 Hemangiosarcoma 1 Glioma 1 Colonic Neoplasms 1

Interventions

Cisplatin 104 Radiotherapy, Intensity-Modulated 59 Gemcitabine 53 toripalimab 35 Fluorouracil 30 Docetaxel 30 Capecitabine 28 Radiotherapy 23 Drug Therapy 20 camrelizumab 19 nimotuzumab 16 nedaplatin 12 Chemoradiotherapy 12 sintilimab 11 apatinib 11 Induction Chemotherapy 11 Immune Checkpoint Inhibitors 11 spartalizumab 10 endostar protein 8 Paclitaxel 8 Cetuximab 8 tislelizumab 7 pembrolizumab 7 Endostatins 7 Bevacizumab 7 anlotinib 6 Radiation 6 Endoscopy 6 fludarabine 5 S 1 (combination) 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Nasopharyngeal Carcinoma × MK 2206 × Clear all

NCT01370070 2017-01-13

MC1079

Chinese University of Hong Kong

Phase 2 Completed

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡